Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 8 | 2025 | 44 | 2.090 |
Why?
|
| Intraabdominal Infections | 9 | 2025 | 10 | 1.940 |
Why?
|
| Anti-Bacterial Agents | 13 | 2025 | 109 | 1.690 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 8 | 2025 | 24 | 1.350 |
Why?
|
| Humans | 42 | 2025 | 5837 | 1.070 |
Why?
|
| Antimicrobial Stewardship | 5 | 2025 | 11 | 1.070 |
Why?
|
| Intensive Care Units | 3 | 2024 | 55 | 0.960 |
Why?
|
| Female | 25 | 2025 | 3346 | 0.930 |
Why?
|
| Candidiasis | 1 | 2025 | 2 | 0.920 |
Why?
|
| Skin | 5 | 2025 | 40 | 0.830 |
Why?
|
| Anti-Infective Agents, Local | 3 | 2024 | 11 | 0.720 |
Why?
|
| Medical Order Entry Systems | 4 | 2025 | 8 | 0.720 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 4 | 2019 | 21 | 0.710 |
Why?
|
| Chlorhexidine | 5 | 2024 | 16 | 0.710 |
Why?
|
| Middle Aged | 13 | 2025 | 1775 | 0.690 |
Why?
|
| Male | 15 | 2025 | 3399 | 0.660 |
Why?
|
| Adult | 14 | 2025 | 1670 | 0.610 |
Why?
|
| beta-Lactamases | 4 | 2025 | 13 | 0.610 |
Why?
|
| Enterobacteriaceae | 2 | 2019 | 8 | 0.560 |
Why?
|
| Aged | 12 | 2025 | 1860 | 0.560 |
Why?
|
| Pregnancy Complications, Infectious | 7 | 2024 | 10 | 0.540 |
Why?
|
| Genomics | 4 | 2025 | 13 | 0.540 |
Why?
|
| Baths | 3 | 2024 | 10 | 0.530 |
Why?
|
| Chicago | 4 | 2025 | 239 | 0.490 |
Why?
|
| Infection Control | 4 | 2024 | 27 | 0.440 |
Why?
|
| Bacterial Toxins | 1 | 2014 | 2 | 0.430 |
Why?
|
| Virulence Factors | 1 | 2014 | 2 | 0.430 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2014 | 3 | 0.430 |
Why?
|
| Nursing Homes | 3 | 2025 | 10 | 0.430 |
Why?
|
| Skin Care | 2 | 2024 | 6 | 0.420 |
Why?
|
| Pregnancy | 8 | 2024 | 103 | 0.420 |
Why?
|
| Anal Canal | 1 | 2014 | 1 | 0.410 |
Why?
|
| Bacteriological Techniques | 1 | 2014 | 2 | 0.410 |
Why?
|
| Culture Media | 1 | 2014 | 4 | 0.410 |
Why?
|
| United States | 10 | 2024 | 502 | 0.410 |
Why?
|
| Mass Screening | 1 | 2014 | 31 | 0.400 |
Why?
|
| Urinary Tract Infections | 2 | 2024 | 9 | 0.390 |
Why?
|
| Respiratory Tract Infections | 2 | 2025 | 5 | 0.390 |
Why?
|
| Long-Term Care | 2 | 2025 | 10 | 0.380 |
Why?
|
| Child | 8 | 2024 | 339 | 0.380 |
Why?
|
| Bacterial Load | 1 | 2012 | 3 | 0.370 |
Why?
|
| Gram-Positive Bacteria | 1 | 2012 | 5 | 0.370 |
Why?
|
| Enterobacteriaceae Infections | 3 | 2021 | 13 | 0.350 |
Why?
|
| Staphylococcal Infections | 4 | 2019 | 30 | 0.340 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2022 | 4 | 0.280 |
Why?
|
| Bacterial Proteins | 5 | 2025 | 17 | 0.270 |
Why?
|
| Hospitalization | 6 | 2025 | 86 | 0.270 |
Why?
|
| Diagnostic Imaging | 5 | 2024 | 24 | 0.270 |
Why?
|
| Klebsiella pneumoniae | 2 | 2020 | 8 | 0.260 |
Why?
|
| Klebsiella Infections | 2 | 2020 | 9 | 0.260 |
Why?
|
| Phylogeny | 2 | 2025 | 14 | 0.260 |
Why?
|
| Vancomycin-Resistant Enterococci | 2 | 2024 | 8 | 0.260 |
Why?
|
| Carrier State | 2 | 2024 | 11 | 0.250 |
Why?
|
| Hospitals | 4 | 2025 | 31 | 0.250 |
Why?
|
| Methicillin Resistance | 1 | 2005 | 2 | 0.230 |
Why?
|
| Daptomycin | 1 | 2005 | 3 | 0.230 |
Why?
|
| Reimbursement, Incentive | 2 | 2024 | 3 | 0.230 |
Why?
|
| Whole Genome Sequencing | 1 | 2025 | 1 | 0.230 |
Why?
|
| Genome, Fungal | 1 | 2025 | 1 | 0.230 |
Why?
|
| Staphylococcus aureus | 1 | 2005 | 17 | 0.230 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2025 | 1 | 0.230 |
Why?
|
| Air Microbiology | 1 | 2025 | 2 | 0.220 |
Why?
|
| Environmental Monitoring | 1 | 2025 | 3 | 0.220 |
Why?
|
| Soft Tissue Infections | 1 | 2025 | 16 | 0.220 |
Why?
|
| Blood Culture | 1 | 2024 | 1 | 0.220 |
Why?
|
| Cholangitis | 1 | 2024 | 1 | 0.220 |
Why?
|
| Abdominal Abscess | 1 | 2024 | 1 | 0.220 |
Why?
|
| Cholecystitis, Acute | 1 | 2024 | 1 | 0.220 |
Why?
|
| Rectum | 1 | 2024 | 10 | 0.220 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2024 | 14 | 0.220 |
Why?
|
| Epidemiological Monitoring | 1 | 2024 | 9 | 0.220 |
Why?
|
| Feces | 1 | 2024 | 10 | 0.220 |
Why?
|
| Appendicitis | 1 | 2024 | 3 | 0.220 |
Why?
|
| Diverticulitis | 1 | 2024 | 5 | 0.210 |
Why?
|
| Patient Discharge | 1 | 2024 | 44 | 0.210 |
Why?
|
| Health Facilities | 1 | 2024 | 7 | 0.210 |
Why?
|
| Bacterial Infections | 1 | 2024 | 13 | 0.210 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 2 | 2021 | 5 | 0.210 |
Why?
|
| Pneumonia | 1 | 2024 | 25 | 0.210 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 3 | 0.200 |
Why?
|
| Clostridium Infections | 1 | 2023 | 7 | 0.200 |
Why?
|
| Candida | 1 | 2023 | 2 | 0.190 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 1034 | 0.180 |
Why?
|
| Viruses | 1 | 2020 | 1 | 0.170 |
Why?
|
| Vancomycin Resistance | 1 | 2000 | 2 | 0.160 |
Why?
|
| Enterococcus | 1 | 2000 | 3 | 0.160 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2000 | 5 | 0.160 |
Why?
|
| Fluoroquinolones | 1 | 2019 | 5 | 0.150 |
Why?
|
| Plasmids | 1 | 2019 | 17 | 0.150 |
Why?
|
| Disinfection | 1 | 2019 | 2 | 0.150 |
Why?
|
| Mupirocin | 1 | 2019 | 2 | 0.150 |
Why?
|
| Community-Acquired Infections | 2 | 2019 | 12 | 0.140 |
Why?
|
| Melioidosis | 1 | 2015 | 3 | 0.120 |
Why?
|
| Burkholderia pseudomallei | 1 | 2015 | 3 | 0.120 |
Why?
|
| Travel | 1 | 2015 | 8 | 0.120 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2019 | 10 | 0.110 |
Why?
|
| Acute Disease | 2 | 2024 | 47 | 0.110 |
Why?
|
| Nasal Cavity | 1 | 2014 | 5 | 0.110 |
Why?
|
| Pharynx | 1 | 2014 | 5 | 0.110 |
Why?
|
| Delivery of Health Care | 2 | 2024 | 23 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2024 | 112 | 0.100 |
Why?
|
| Bacteremia | 2 | 2005 | 13 | 0.100 |
Why?
|
| Mandatory Reporting | 1 | 2013 | 1 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2013 | 23 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 125 | 0.100 |
Why?
|
| Public Health | 2 | 2024 | 12 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2012 | 36 | 0.090 |
Why?
|
| Catheter-Related Infections | 1 | 2012 | 13 | 0.090 |
Why?
|
| California | 2 | 2024 | 16 | 0.090 |
Why?
|
| Administration, Intranasal | 2 | 2024 | 7 | 0.090 |
Why?
|
| Disease Outbreaks | 2 | 2023 | 15 | 0.090 |
Why?
|
| Time Factors | 1 | 2012 | 374 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2012 | 406 | 0.080 |
Why?
|
| DNA, Bacterial | 2 | 2019 | 9 | 0.060 |
Why?
|
| Osteomyelitis | 1 | 2005 | 5 | 0.060 |
Why?
|
| Lumbosacral Region | 1 | 2005 | 12 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2005 | 24 | 0.060 |
Why?
|
| Genome, Viral | 1 | 2025 | 7 | 0.060 |
Why?
|
| Metagenomics | 1 | 2025 | 3 | 0.060 |
Why?
|
| Bacteria | 1 | 2025 | 8 | 0.060 |
Why?
|
| Microbiota | 1 | 2025 | 19 | 0.050 |
Why?
|
| Lumbar Vertebrae | 1 | 2005 | 77 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2024 | 2 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2024 | 5 | 0.050 |
Why?
|
| Iodophors | 1 | 2024 | 3 | 0.050 |
Why?
|
| Universal Precautions | 1 | 2024 | 3 | 0.050 |
Why?
|
| Patient Transfer | 1 | 2024 | 9 | 0.050 |
Why?
|
| Length of Stay | 1 | 2024 | 45 | 0.050 |
Why?
|
| Benchmarking | 1 | 2024 | 5 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2024 | 34 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 187 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2023 | 11 | 0.050 |
Why?
|
| Gelatinases | 1 | 2002 | 2 | 0.050 |
Why?
|
| Enterococcus faecalis | 1 | 2002 | 2 | 0.050 |
Why?
|
| Hemolysin Proteins | 1 | 2002 | 2 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 284 | 0.050 |
Why?
|
| Adolescent | 2 | 2019 | 488 | 0.040 |
Why?
|
| Ecosystem | 1 | 2021 | 7 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 2 | 0.040 |
Why?
|
| Hand Disinfection | 1 | 2000 | 2 | 0.040 |
Why?
|
| Disease Reservoirs | 1 | 2000 | 4 | 0.040 |
Why?
|
| Mathematics | 1 | 2000 | 25 | 0.040 |
Why?
|
| Hand | 1 | 2000 | 9 | 0.040 |
Why?
|
| Models, Biological | 1 | 2000 | 132 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2019 | 153 | 0.040 |
Why?
|
| Prevalence | 1 | 2019 | 72 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 15 | 0.040 |
Why?
|
| Hygiene | 1 | 2019 | 5 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 8 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2019 | 136 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 29 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2019 | 174 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 98 | 0.040 |
Why?
|
| Infant | 1 | 2019 | 184 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 333 | 0.030 |
Why?
|
| Genitalia, Female | 1 | 1997 | 5 | 0.030 |
Why?
|
| Young Adult | 1 | 2019 | 421 | 0.030 |
Why?
|
| Risk Factors | 1 | 2019 | 499 | 0.030 |
Why?
|
| HIV-1 | 1 | 1997 | 74 | 0.030 |
Why?
|
| HIV Infections | 1 | 1997 | 135 | 0.030 |
Why?
|
| Mexico | 1 | 2015 | 6 | 0.030 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2014 | 4 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2014 | 13 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2014 | 29 | 0.030 |
Why?
|
| Phenotype | 1 | 2014 | 96 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2013 | 20 | 0.030 |
Why?
|
| Asphyxia Neonatorum | 1 | 1984 | 1 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1984 | 20 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1984 | 30 | 0.010 |
Why?
|
| Virulence | 1 | 2002 | 2 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2002 | 11 | 0.010 |
Why?
|
| Mortality | 1 | 2002 | 22 | 0.010 |
Why?
|
| Heating | 1 | 1997 | 3 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 1997 | 6 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1997 | 5 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 1997 | 9 | 0.010 |
Why?
|
| Virus Latency | 1 | 1997 | 6 | 0.010 |
Why?
|
| HIV Long Terminal Repeat | 1 | 1997 | 7 | 0.010 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1997 | 4 | 0.010 |
Why?
|
| Therapeutic Irrigation | 1 | 1997 | 14 | 0.010 |
Why?
|
| Monocytes | 1 | 1997 | 14 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1997 | 24 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 24 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1997 | 22 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1997 | 44 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1997 | 167 | 0.010 |
Why?
|
| Pyruvates | 1 | 1984 | 1 | 0.000 |
Why?
|
| Lactates | 1 | 1984 | 2 | 0.000 |
Why?
|
| Catecholamines | 1 | 1984 | 3 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1984 | 9 | 0.000 |
Why?
|
| Glycogen | 1 | 1984 | 7 | 0.000 |
Why?
|
| Glucagon | 1 | 1984 | 4 | 0.000 |
Why?
|
| Insulin | 1 | 1984 | 16 | 0.000 |
Why?
|
| Liver | 1 | 1984 | 22 | 0.000 |
Why?
|
| Rats | 1 | 1984 | 282 | 0.000 |
Why?
|
| Animals | 1 | 1984 | 1349 | 0.000 |
Why?
|